Biolase (Biolase) Cash And Cash Equivalents : $6.57 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Biolase Cash And Cash Equivalents?

Biolase's quarterly cash and cash equivalents increased from Jun. 2023 ($6.93 Mil) to Sep. 2023 ($7.81 Mil) but then stayed the same from Sep. 2023 ($7.81 Mil) to Dec. 2023 ($6.57 Mil).

Biolase's annual cash and cash equivalents declined from Dec. 2021 ($29.97 Mil) to Dec. 2022 ($4.18 Mil) but then increased from Dec. 2022 ($4.18 Mil) to Dec. 2023 ($6.57 Mil).

Biolase Cash And Cash Equivalents Historical Data

The historical data trend for Biolase's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Cash And Cash Equivalents Chart

Biolase Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

5.79

17.56

29.97

4.18

6.57

Biolase Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															4.18	6.53	6.93	7.81	6.57

Biolase Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Biolase (NAS:BIOL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Biolase Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Biolase's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolase (Biolase) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BTH0:Germany

Address

27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610

Website

https://www.biolase.com

Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Executives

Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md	director	500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright	officer: Chief Financial Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor	officer: Chief Operating Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver	director, officer: President & CEO	C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg	10 percent owner	C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla	director	3299 CAMBRIDGE AVE, BRONX NY 10463